1541 Stock Overview
A biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$12.46 |
| 52 Week High | HK$23.15 |
| 52 Week Low | HK$11.86 |
| Beta | 0 |
| 11 Month Change | 1.30% |
| 3 Month Change | -16.82% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -36.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1541 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -3.6% | 6.5% | -1.7% |
| 1Y | n/a | -26.3% | -5.9% |
Return vs Industry: Insufficient data to determine how 1541 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 1541 performed against the Hong Kong Market.
Price Volatility
| 1541 volatility | |
|---|---|
| 1541 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 1541 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 1541's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 145 | Tian Wenzhi | www.immuneonco.com |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. Its core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; IMM2902 that in Phase I clinical trial for the treatment of HER2-positive and low expressing solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Fundamentals Summary
| 1541 fundamental statistics | |
|---|---|
| Market cap | HK$4.66b |
| Earnings (TTM) | -HK$414.20m |
| Revenue (TTM) | HK$8.55m |
545.3x
P/S Ratio-11.3x
P/E RatioIs 1541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1541 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.83m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥7.83m |
| Other Expenses | CN¥387.29m |
| Earnings | -CN¥379.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,844.98% |
| Debt/Equity Ratio | 8.0% |
How did 1541 perform over the long term?
See historical performance and comparison